ENS 56318: Difference between revisions
Jump to navigation
Jump to search
StriderTol (talk | contribs) (StriderTol Bot change) |
StriderTol (talk | contribs) (StriderTol Bot change) |
||
| Line 12: | Line 12: | ||
| emergency class = Non Emergency | | emergency class = Non Emergency | ||
| notification date = 01/20/2023 09:18 | | notification date = 01/20/2023 09:18 | ||
| retracted = Yes | |||
| notification by = Sandra Phillips | | notification by = Sandra Phillips | ||
| NRC officer = Kerby Scales | | NRC officer = Kerby Scales | ||
| event date = 01/19/2023 10:00 EST | | event date = 01/19/2023 10:00 EST | ||
| last update date = 01 | | last update date = 02/01/2023 | ||
| title = Potential Medical Event | | title = Potential Medical Event | ||
| event text = The following is a summary of information provided by the licensee via email and phone: | | event text = The following is a summary of information provided by the licensee via email and phone: | ||
A patient, accompanied by her daughter who is the patient's preferred translator, was receiving the first of four Lutathera infusions. The physician, registered nurse, nuclear medicine personnel and radiological safety team members were present for the infusion. The Lutathera infusion was performed per protocol without any issue. Post infusion it was determined through the patient's daughter that the patient had had a lanreotide injection last week on 1/12/23. Per protocol Lutathera is to be given four weeks after a lanreotide/octreotide injection has been administered. | A patient, accompanied by her daughter who is the patient's preferred translator, was receiving the first of four Lutathera infusions. The physician, registered nurse, nuclear medicine personnel and radiological safety team members were present for the infusion. The Lutathera infusion was performed per protocol without any issue. Post infusion it was determined through the patient's daughter that the patient had had a lanreotide injection last week on 1/12/23. Per protocol Lutathera is to be given four weeks after a lanreotide/octreotide injection has been administered. | ||
A Medical Event may indicate potential problems in a medical facility's use of radioactive materials. It does not necessarily result in harm to the patient. | A Medical Event may indicate potential problems in a medical facility's use of radioactive materials. It does not necessarily result in harm to the patient. | ||
| URL = https://www.nrc.gov/reading-rm/doc-collections/event-status/event/2023/ | * * * RETRACTION ON 2/1/23 AT 1040 EST FROM SANDRA PHILLIPS TO ADAM KOZIOL * * * | ||
The following information was provided by the licensee via telephone: | |||
Further review from hospital staff in coordination with NRC Medical Health Team determined this is not a medical event. | |||
Notified R1DO (Lally) and NMSS (email). | |||
| URL = https://www.nrc.gov/reading-rm/doc-collections/event-status/event/2023/20230202en.html#en56318 | |||
}} | }} | ||
{{ENS-Nav}} | {{ENS-Nav}} | ||
Latest revision as of 15:59, 4 January 2024
| Where | |
|---|---|
| Hartford Hospital Hartford, Connecticut (NRC Region 1) | |
| License number: | 06-00253-04 |
| Organization: | Hartford Hospital |
| Reporting | |
| 10 CFR 35.3045(a)(1) | |
| Time - Person (Reporting Time:+18.3 h0.763 days <br />0.109 weeks <br />0.0251 months <br />) | |
| Opened: | Sandra Phillips 09:18 Jan 20, 2023 |
| NRC Officer: | Kerby Scales |
| Last Updated: | Feb 1, 2023 |
| 56318 - NRC Website | |